This report describes and evaluates the animal testing and non-animal alternative testing market in major geographies.Animal testing or experiment on animals done in the early stages of drug development and for toxicity and safety assessment of medical devices, chemicals, pesticides, cosmetics, and food compounds. Animal experiments are necessary before testing on humans mainly to evaluate toxicity, pharmacokinetics, and safety of a drug or a chemical.
However, there is an increasing pressure from the animal welfare organizations on governmental agencies and companies to use non-animal alternative testing technologies. These technologies include in-vitro cell and tissue cultures, organ-on-chip, computer simulations, 3D bio printing of tissues, and synthetic skin substitutes, among others. Industries such as pharmaceuticals, medical devices, chemicals & pesticides and food are increasingly adopting these technologies to replace animal testing.
Animal Testing:
The global animal testing market was valued at $10.74 billion in 2019 and the market is expected to grow at a compound annual growth rate (CAGR) of 4.27% during 2019-2025 and at a CAGR of 2.46% during 2025-2035.
Request Research Sample: https://altusmarketresearch.com/reports/sample/43212
The growth of the animal testing market in the USA and Japan is mainly due to the rise in R&D activities in end-use industries, and regulations to conduct animal experiments before testing on humans. However, the slow anticipated future growth rates (from 2021 to 2035) can be attributed to the requirement from federal agencies on biopharma companies to adopt 3R principles (i.e. to replace, reduce, and refine animals used in the laboratory research), protests from animal welfare organizations. In 2021, the US Environmental Protection Agency (EPA) decided to rule out mammal testing for chemicals by 2035, and increasing preference by end-use industries towards the adoption of non-animal testing technologies.
Non-Animal Testing
The global non-animal alternative testing market was valued at $1.110 billion in 2019. The market is expected to grow at a CAGR of 10.40% during 2019-2025.
The USA’s non-animal alternative testing technology market was valued at $0.336 billion in 2019. The USA’s market is forecast to grow at a CAGR of 11.99% through 2025. Japan's non-animal alternative testing technology market was valued at $0.058 billion in 2019 and the market is forecast to grow at a CAGR of 6.79% through 2025.
The growth in the non-animal alternative testing market is mainly due to the adoption of the 3R principles by both regulatory agencies, and end-use companies, especially in the cosmetic industry. The adoption of alternative technologies is expected to grow after 2026 post regulatory agencies’ validation and approval.
Scope
Markets Covered:
By End User Industry: Pharmaceuticals; Academic Research; Medical Devices; Chemicals And Pesticides; Cosmetics; Others
By Animal Type: Mice; Rat; Frogs; Fish; Birds; Guinea pig; Hamster; Rabbits; Sheep; Dogs; Cats; Monkeys; Pigs; Others
Companies Mentioned: Cyprotex; Bio-Rad Laboratories, Inc.; MatTek Corporation; Emulate, Inc; BioIVT
Countries: Australia; China; France; Germany; Japan; UK; USA; Canada
Regions: Asia-Pacific; Europe; North America; Rest Of The World
Time series: Five years historic and ten years forecast.
Data: Ratios of market size and growth to related markets; GDP proportions; expenditure per capita; animal testing and non-animal alternative testing indicators comparison.
Data segmentations: country and regional historic and forecast data; market share of competitors; market segments.
Sourcing and Referencing: Data and analysis throughout the report is sourced using end notes.
